BTIG Maintains Buy Rating and $29 Price Target for ArriVent BioPharma
BTIG analyst Jeet Mukherjee has reiterated a Buy rating and a $29.00 price target on ArriVent BioPharma, Inc.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BTIG analyst Jeet Mukherjee has reiterated a Buy rating and a $29.00 price target on ArriVent BioPharma, Inc.
Cantor Fitzgerald reaffirmed an Overweight rating for ArriVent BioPharma, Inc. on November 12, 2026.
Several financial analysts maintained buy ratings and updated price targets for ArriVent BioPharma (AVBP) on November 11, 2026.
Truist Securities has maintained its 'Buy' rating on ArriVent BioPharma while increasing the price target from $21.00 to $24.00 per share.
ArriVent BioPharma announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including the ALPACCA trial and ARR-217.